Regeneron Pharmaceuticals, Inc.

About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. is a leading biotechnology company that focuses on the discovery, development, and commercialization of innovative medicines for the treatment of serious diseases. Founded in 1988, the company has established itself as a pioneer in the field of genetic research and drug development.

With a commitment to scientific excellence, Regeneron employs a unique VelociSuite® technology platform that accelerates the process of drug discovery. This platform enables the rapid identification of potential therapeutic candidates, which are then rigorously tested in clinical trials.

Regeneron’s product portfolio includes several blockbuster drugs that have transformed the treatment landscape for conditions such as cancer, eye diseases, and inflammatory disorders. The company’s flagship product, EYLEA®, is widely recognized for its effectiveness in treating retinal diseases.

In addition to its focus on existing therapies, Regeneron is dedicated to advancing the frontiers of medicine through continuous research and development. The company collaborates with various academic institutions and industry partners to explore new therapeutic areas and improve patient outcomes.

Regeneron is also committed to corporate social responsibility, actively engaging in initiatives that promote access to healthcare and support local communities. The company believes in the importance of ethical practices and transparency in all its operations.

Headquartered in Tarrytown, New York, Regeneron has a global presence, with facilities and partnerships extending across the United States and Europe. The company’s workforce is comprised of highly skilled professionals who are passionate about making a difference in the lives of patients.

As Regeneron continues to grow, it remains focused on its mission to use science to bring new medicines to patients in need, ultimately striving to improve health outcomes worldwide.